Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 1,503 shares, a decline of 87.7% from the May 31st total of 12,174 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 6,655 shares, the days-to-cover ratio is presently 0.2 days.

Santen Pharmaceutical Price Performance

Shares of SNPHY stock traded down $0.34 during trading hours on Friday, reaching $12.76. 547 shares of the company’s stock were exchanged, compared to its average volume of 12,431. The company has a market cap of $4.11 billion and a P/E ratio of 0.10. The company’s 50 day moving average is $11.55 and its two-hundred day moving average is $11.13. Santen Pharmaceutical has a 1 year low of $9.22 and a 1 year high of $13.10.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, Santen Pharmaceutical currently has an average rating of “Hold”.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.